- Home
- LFT vs NSRX Comparison
LFT vs NSRX Comparison
Compare LFT & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LFT | NSRX |
|---|---|---|
| Founded | 2012 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.8M | 38.9M |
| IPO Year | 2012 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LFT | NSRX |
|---|---|---|
| Price | $5.16 | $3.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $19.67 |
| AVG Volume (30 Days) | ★ 63.6K | 8.5K |
| Earning Date | 05-13-2026 | 03-25-2026 |
| Dividend Yield | ★ 18.49% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $668.15 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.58 | $1.98 |
| 52 Week High | $6.94 | $9.50 |
Technical Indicators
Market Signals| Indicator | LFT | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 69.27 | 51.38 |
| Support Level | $0.91 | $2.97 |
| Resistance Level | $6.94 | $4.49 |
| Average True Range (ATR) | 0.20 | 0.31 |
| MACD | 0.05 | -0.03 |
| Stochastic Oscillator | 73.07 | 59.03 |
Price Performance
Historical ComparisonAbout LFT Lument Finance Trust Inc.
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.
About NSRX Nasus Pharma Ltd. Ordinary Shares
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.